009420 - Hanall Biopharma Co., Ltd.

009420 Summary

Biopharma

Stock Price & Overview

₩54,700 +800 (+1.48%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩54,700 ≈ US$39 · Market cap ₩2.9tn (≈ $2.0bn)

009420 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	155.2	138.9	134.9	110.0	101.6	88.6	108.5	91.8	84.2	82.9	80.0
Cost of Revenue	74.3	65.6	59.7	48.0	41.3	38.0	45.7	42.8	41.6	44.4	43.1
Gross Profit	80.9	73.3	75.2	62.0	60.3	50.7	62.8	49.0	42.7	38.5	36.9
Selling, General & Administrative	81.8	73.1	73.0	44.0	39.8	35.4	35.6	33.0	29.3	—	—
Operating Income	-0.9	0.2	2.2	1.5	10.1	5.9	17.1	5.5	3.5	0.3	-4.3
Finance Income	0.9	1.2	3.6	2.4	0.9	13.3	3.7	3.9	1.3	1.2	1.0
Finance Costs	5.0	0.9	0.9	1.7	0.5	0.2	1.3	1.2	1.0	0.2	0.8
Pretax Income	-6.2	-0.2	3.2	1.9	8.7	19.2	17.5	4.0	2.6	1.7	-4.8
Income Tax Expense	-0.6	1.6	-0.3	1.7	-0.2	-0.5	-1.7	0.7	-3.2	0.4	2.3
Net Income	-5.6	-1.8	3.5	0.3	8.9	19.8	19.2	3.3	5.8	2.0	-7.1
Total Comprehensive Income	-6.2	-19.9	15.5	12.8	-19.6	39.9	23.0	5.2	6.3	2.2	-9.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	225.2	212.9	239.7	213.5	198.5	220.1	191.4	162.3	168.7	124.7	117.1
Current Assets	84.9	85.4	113.6	111.8	118.8	129.4	134.3	128.4	138.4	96.4	92.8
Cash & Cash Equivalents	24.7	16.4	33.7	16.8	12.8	4.2	6.1	22.7	41.9	9.5	9.3
Inventories	38.1	37.7	32.4	25.2	20.4	19.9	13.7	15.5	16.5	17.6	19.9
Trade Receivables	19.4	20.1	22.5	30.7	15.6	15.7	22.6	17.5	19.1	22.7	23.5
Non-current Assets	140.3	127.5	126.2	101.7	79.7	90.8	57.1	33.9	30.3	28.3	24.4
Property, Plant & Equipment	15.9	17.0	18.1	17.7	17.7	14.9	14.4	13.8	13.4	13.8	12.2
Intangible Assets	64.6	51.8	32.6	23.8	19.1	15.1	10.7	5.5	10.2	11.7	9.7
Total Liabilities	63.5	44.5	53.5	45.2	35.0	38.9	51.0	45.4	57.5	20.4	21.9
Current Liabilities	44.5	34.7	37.7	28.5	22.1	23.1	27.4	21.8	52.8	14.4	14.1
Non-current Liabilities	19.1	9.8	15.9	16.7	12.9	15.8	23.6	23.6	4.7	6.0	7.8
Total Equity	161.7	168.4	186.2	168.3	163.5	181.3	140.4	116.9	111.2	104.4	95.2
Share Capital	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1	25.8
Retained Earnings	21.1	26.5	31.4	29.4	26.4	17.6	-3.1	-21.3	-24.5	-30.3	-32.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-2.3	9.4	29.6	25.2	0.8	0.9	20.5	-3.0	42.1	4.0	-0.5
Cash from Investing Activities	-18.8	-27.5	-11.9	-10.6	8.0	-2.3	-36.6	-16.1	-10.1	-10.8	-36.3
Purchase of Property, Plant & Equipment	0.9	1.6	2.4	—	—	—	—	—	—	—	—
Cash from Financing Activities	29.6	0.8	-0.8	-10.6	-0.3	-0.5	-0.5	—	0.6	7.1	38.5
Net Change in Cash	8.4	-17.3	16.9	4.0	8.6	-1.9	-16.6	-19.2	32.4	0.2	1.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	44.3	40.0	37.5	40.8	40.7	36.2	36.4	36.8	31.6	34.1
Cost of Revenue	19.5	18.7	18.9	19.8	18.7	16.9	17.4	17.0	15.7	15.5
Gross Profit	24.8	21.3	18.7	21.0	21.9	19.2	19.0	19.8	15.9	18.6
Selling, General & Administrative	19.2	20.5	36.4	15.9	14.9	14.5	13.9	13.4	12.6	13.2
Operating Income	5.6	0.8	-2.0	0.3	1.1	-0.4	2.7	0.4	-3.1	0.1
Finance Income	0.4	0.2	0.2	0.1	0.3	0.3	0.2	0.5	0.2	0.3
Finance Costs	0.7	1.0	4.5	0.1	0.1	0.3	0.4	0.1	0.2	0.2
Pretax Income	-21.5	0.6	-7.2	0.3	1.0	-0.4	2.4	0.5	-3.1	-0.0
Income Tax Expense	-2.3	0.3	-0.9	0.0	0.4	-0.2	0.8	0.3	0.2	0.3
Net Income	-19.2	0.3	-6.2	0.3	0.6	-0.2	1.6	0.2	-3.3	-0.3
Total Comprehensive Income	-2.2	1.2	4.0	1.0	-2.1	-9.1	-4.1	0.9	-8.4	-8.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	240.5	243.8	225.2	201.8	190.7	195.7	212.9	212.9	212.9	221.5
Current Assets	92.9	102.1	84.9	75.3	67.7	74.2	85.4	86.1	91.4	103.8
Cash & Cash Equivalents	30.2	36.2	24.7	11.9	8.5	13.5	16.4	18.9	17.7	30.3
Inventories	40.8	45.5	38.1	40.7	38.0	40.6	37.7	34.3	30.8	31.5
Trade Receivables	21.1	17.7	19.4	19.0	18.1	16.6	20.1	22.1	22.4	21.8
Non-current Assets	147.6	141.8	140.3	126.5	123.0	121.5	127.5	126.8	121.5	117.8
Property, Plant & Equipment	14.6	15.4	15.9	16.3	16.3	16.7	17.0	17.3	17.1	17.5
Intangible Assets	56.1	67.3	64.6	61.5	58.8	55.4	51.8	46.4	41.1	34.1
Total Liabilities	78.9	81.5	63.5	44.2	34.6	36.4	44.5	41.6	42.6	43.3
Current Liabilities	62.2	63.8	44.5	37.5	27.1	27.9	34.7	30.1	29.2	29.7
Non-current Liabilities	16.7	17.6	19.1	6.6	7.5	8.5	9.8	11.5	13.5	13.7
Total Equity	161.6	162.4	161.7	157.7	156.1	159.3	168.4	171.4	170.3	178.2
Share Capital	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1	26.1
Retained Earnings	2.2	21.4	21.1	27.2	26.9	26.3	26.5	27.9	27.7	31.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-6.7	2.5	-12.7	7.3	2.1	0.9	3.5	7.3	-2.2	0.8
Cash from Investing Activities	-1.9	-3.3	-5.2	-4.2	-5.7	-3.8	-7.5	-5.8	-10.1	-4.1
Purchase of Property, Plant & Equipment	0.1	0.5	—	—	—	—	—	—	—	—
Cash from Financing Activities	2.5	12.2	30.7	0.2	-1.4	0.1	1.4	-0.2	-0.2	-0.1
Net Change in Cash	-6.0	11.4	12.8	3.4	-5.0	-2.8	-2.5	1.2	-12.6	-3.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

009420 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	155.2	+11.7%	+12.2%	+11.9%	+6.8%
Operating income	-0.9	—	—	—	—
Net income	-5.6	—	—	—	—
EPS	₩-106	—	—	—	—
Operating cash flow	-2.3	—	—	—	—
Shareholders' equity	161.7	-4.0%	-1.3%	-2.3%	+5.4%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

009420 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	52.1%	52.8%	55.7%	56.3%	59.4%	57.2%
Operating margin	-0.6%	0.2%	1.6%	1.4%	9.9%	6.7%
Net margin	-3.6%	-1.3%	2.6%	0.2%	8.8%	22.3%
Return on equity	-3.4%	-1.0%	2.0%	0.2%	5.2%	12.3%
Return on assets	-2.5%	-0.8%	1.5%	0.1%	4.3%	9.6%
Operating cash flow / revenue	-1.5%	6.7%	22.0%	22.9%	0.8%	1.0%
Capex / revenue	0.6%	1.2%	1.8%	—	—	—

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 009420

Symbol	Last Price
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.